Overview of Dr. Meyers
Dr. Paul Meyers is a pediatric hematologist/oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Sloan Kettering Cancer Center. He received his medical degree from Icahn School of Medicine at Mount Sinai and has been in practice 44 years. He also speaks multiple languages, including Spanish and French. He is experienced in osteosarcoma, ewing sarcoma, rhabdomyosarcoma, pediatric sarcomas, and combined modality therapy. He has more than 225 publications and over 20,000 citings.
Office
1275 York Avenue
New York, NY 10065
Education & Training
- Memorial Hospital1978 - 1979
- Sloan-Kettering Institute1977 - 1979
- Cornell Medical Center1976 - 1976
- Mt Sinai Hospital1974 - 1976
- Mt Sinai Hospital1973 - 1974
- Icahn School of Medicine at Mount SinaiClass of 1973
- Brown UniversityAB, Cum laude, 1966 - 1971
Certifications & Licensure
- FL State Medical License 2022 - Present
- NY State Medical License 1974 - 2026
- NJ State Medical License 1982 - 2025
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- New York Magazine: Top Doctors Castle Connolly, 2002-2014
- America's Top Doctors Castle Connolly, 2002-2014
- Top Doctors: New York Metro Area Castle Connolly, 2002-2014
- Join now to see all
Clinical Trials
- Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor Start of enrollment: 1995 Apr 01
- Combination Chemotherapy and Biological Therapy in Treating Patients With High-Risk Ewing's Sarcoma Start of enrollment: 1998 Sep 01
- Trastuzumab in Treating Patients With Recurrent Osteosarcoma Start of enrollment: 1999 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- 31 citationsDesmoplastic small round cell tumor 20 years after its discoveryJaume Mora, Shakeel Modak, Nai-Kong V. Cheung, Paul A. Meyers, Enrique de Alava
Future Oncology. 2015-03-25 - 116 citationsA recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations.Shinji Kohsaka, Neerav Shukla, Nabahet Ameur, Tatsuo Ito, Charlotte K.Y. Ng
Nature Genetics. 2014-06-01 - 44 citationsPre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma.Srikanth R. Ambati, Eloisi Caldas Lopes, Kohji Kosugi, Ullas Mony, Ahmet Zehir
Molecular Oncology. 2014-03-01
Journal Articles
- Identification of lactoferrin as the granulocyte-derived inhibitor of colony-stimulating activity production.Broxmeyer HE, Smithyman A, Eger RR, Meyers PA, de Sousa M, J Exp Med. 1978 Oct 1;148(4):1052-67
- Inhibition of human erythropoietic colony formation in culture by treatment with Ia antisera.Winchester RJ, Meyers PA, Broxmeyer HE, Wang CY, Moore MA, Kunkel HG, J Exp Med. 1978 Aug 1;148(2):613-8
- Characteristics of bone marrow and blood cells in human leukemia that produce leukemia inhibitory activity (LIA).Broxmeyer HE, Ralph P, Margolis V, Nakoinz I, Meyers PA, Kapoor N, and Moore MAS., Leukemia Research 1979; 3:193-203
- Join now to see all
Books/Book Chapters
Lectures
- The addition of cycles of irinotecan/temozolomide (i/T) to cycles of vincristine, doxorubicin, cyclophosphamide (VDC) and cycles of ifosfamide, etoposide (IE) for the ...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Other
- High dose therapy with autologous stem cell rescue for pediatric sarcomas.Meyers PA, ASCO Education Book
- Holcombe Grier Faculty of 1000 Medicine: evaluations for Meyers PA et al.Paul A. Meyers, Cindy Schwartz, Mark Krailo, Eugenie Kleinerman, Donna Betcher, William Ferguson, Mark Gebhardt, Allen Goorin, Helen Nadel, Michael Nieder, Gene Sigel,..., J Clin Oncol 2008 Feb 1 26 (4) :633-8
http://www.f1000medicine.com/article/id/1100377/evaluation - Response to Osteosarcoma: Time to Move On?Meyers PA, Kleinerman E, European Journal of Cancer
http://www.ecco-org.eu/News/News/EJC-Correspondence/Latest-Correspondence/Osteosarcoma-Time-to-move-
Press Mentions
- Oncternal Therapeutics Announces Presentation of Interim Clinical Data on TK216, Its First-in-Class, Targeted ETS Inhibitor, in Patients with Relapsed or Refractory Ewing Sarcoma at the CTOS 2019 Annual MeetingNovember 14th, 2019
- Oncternal Therapeutics Announces Presentation of Case Study of TK216 in Ewing Sarcoma Given at the Children’s Oncology Group MeetingNovember 5th, 2019
- Salarius Pharmaceuticals Adds Memorial Sloan Kettering Cancer Center and Nationwide Children’s Hospital as Clinical Sites for Phase 1/2 Trial of Seclidemstat in Ewing SarcomaOctober 8th, 2019
Grant Support
- Core BNational Cancer Institute2005–2009
Professional Memberships
- Member
- Member
- American Society of Pediatric Hematology/OncologyMember
- Connective Tissue Oncology SocietyMember
Other Languages
- Spanish, French
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: